With a similar methodology, Deken and colleagues also tested the combination of BRAFi or MEKi therapy with anti-PD-1 immunotherapy and observed increased tumor reduction in response to the combinatorial therapy, in comparison to RAS–ERK signal-targeted therapy alone [158]. The gene discussed is MAPK1; the disease is neoplasm.